Form 4: Neogenomics Executive Greg D. Aunan Reports Stock Transactions
SEC Form 4 Filing
Greg D. Aunan, Chief Accounting Officer of Neogenomics, reports the vesting of restricted stock units and subsequent transactions to cover tax obligations.
Summary
- On May 1, 2025, Greg D. Aunan, Chief Accounting Officer of Neogenomics Inc., had restricted stock units vest.
- 937 shares were surrendered to cover tax obligations related to the vesting of restricted stock.
- 5,372 restricted stock units were released and converted into common stock on May 2, 2025.
- 1,309 shares were disposed of to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
- Following these transactions, Aunan directly owns 17,579 shares of common stock.
- Aunan also holds options to purchase 86,803 shares of common stock at prices ranging from $11.86 to $14.62, and 35,088 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Comparison to Industry Standards
- Executive compensation packages including stock options and restricted stock units are standard practice in publicly traded companies, particularly in the biotech and healthcare sectors.
- The vesting schedules and terms of the options and RSUs appear typical for executive compensation plans.
- Similar companies such as Exact Sciences, Guardant Health, and Invitae also utilize stock-based compensation as part of their executive pay structures.
Stakeholder Impact
- The transactions have a minor dilutive effect on existing shareholders due to the issuance of new shares upon vesting of restricted stock units.
- The reporting provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 05/01/2023 | Mr. Aunan was granted 28,662 stock options. |
| 05/02/2024 | Mr. Aunan was granted 26,978 stock options and 16,117 restricted stock units. |
| 02/21/2025 | Mr. Aunan was granted 31,163 stock options and 18,971 restricted stock units. |
| 05/01/2025 | Vesting of restricted stock; 937 shares surrendered for tax obligations. |
| 05/02/2025 | Release of 5,372 restricted stock units; disposition of 1,309 shares for tax withholding. |
| 05/05/2025 | Date of Form 4 filing. |
| 05/01/2030 | Expiration date for some stock options. |
| 05/02/2034 | Expiration date for some stock options. |
| 02/21/2035 | Expiration date for some stock options. |
Keywords
Form 4, Neogenomics, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading, Aunan, NEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.